Introduction
============

Soft-tissue sarcomas (STSs) are mesenchymal-origin neoplasms characterized by locally aggressive behavior and a propensity for metastases [@B1]. Intra-lesional heterogeneity, a well-documented phenomenon in STSs [@B2]-[@B8], can lead to imaging characteristics on US, CT, MRI, and ^18^F-fluorodeoxyglucose (FDG) PET that can be confused with those of benign fluid collections (BFs), such as hematomas, abscesses, and post-operative fluid collections [@B3], [@B9]-[@B33].

This overlap in imaging appearance leads to diagnostic dilemmas in two main clinical situations: at initial diagnosis of a soft-tissue mass, and in differentiation of recurrent STS from a BF on post-operative imaging. In either setting, the clinician must decide between biopsy and short-term follow-up imaging, each with its own limitations and important implications for patient care. Biopsy of all suspected lesions would not only be costly, but sampling error can lead to equivocal results. Follow-up imaging can avoid this issue by demonstrating growth, stability, or regression, but can delay the diagnosis and appropriate treatment of malignant lesions.

^18^F-FDG PET-CT offers the potential of non-invasively helping to make this distinction. However, previous studies of differentiating STSs from benign lesions have met with variable success and have included few or no BFs [@B2], [@B13], [@B34]-[@B36]. In addition, the majority of these studies have used the degree of ^18^F-FDG avidity, as assessed by metrics such as standardized uptake values (SUVs), while ignoring other data available in ^18^F-FDG PET examinations, such as the spatial pattern of ^18^F-FDG avidity (SP). SP has not been as extensively investigated as SUV [@B36]-[@B42], and may provide additional information about the biological behavior of soft-tissue lesions on ^18^F-FDG PET [@B37].

This study will test two hypotheses about the use of ^18^F-FDG PET-CT in differentiation of STSs and BFs. We hypothesized that 1) ^18^F-FDG PET-CT can differentiate STSs from BFs, and 2) SP can provide useful information in differentiating STSs from BFs in addition to that provided by SUV~max~.

Materials and Methods
=====================

Patient Population
------------------

Institutional review board approval was obtained for this HIPAA-compliant protocol. A retrospective study was performed using a search of FDG-PET/CT reports from 1/1/2006 to 12/31/2011 using keywords \"hematoma,\" \"seroma,\" \"abscess,\" and \"sarcoma.\" Reports were reviewed for all 3,938 cases. Images were reviewed when a report was unclear or indicated the presence of an STS or BF in the extremity. A total of 100 cases (44 BFs and 56 primary, recurrent, or metastatic STSs) met our inclusion criteria (Table [1](#T1){ref-type="table"}). We limited the study to lesions in the extremities in order to decrease the likelihood of interpretation errors caused by normal adjacent structures such as bowel. When multiple studies were available from the same patient, the study on which the finding first appeared was selected. In cases of multiple lesions, only a single representative lesion from the patient was selected in order to avoid the bias toward malignancy when a large numbers of lesions were present. The readers were directed to the specific lesion in question prior to opening the study. The reference standard for STS was biopsy. The reference standard for BF was biopsy, decrease in size, or stability for at least 6 months off treatment as per imaging, or development immediately following surgery (too quickly for a malignancy to typically develop). Abscesses were confirmed by aspiration and microbiological analysis.

Imaging
-------

All ^18^F-FDG PET/CTs were performed at our institution according to standard guidelines and uniform image acquisition and processing protocols. Patients were instructed to fast for at least 6 hours prior to imaging and had a measured blood glucose level of less than 150 mg/dL at the time of radiopharmaceutical administration. Patients received 10 to 20 mCi of ^18^F-FDG, and were allowed to rest quietly in a darkened room for about 60 minutes before images were acquired on a PET/CT scanner (Discovery, GE Healthcare, Milwaukee, WI). CT images were acquired without oral or intravenous contrast, and used for attenuation correction of PET data.

Four readers with 7 years, 6 years, 6 years, and 3 years of experience in interpretation of ^18^F-FDG PET/CT at a large cancer center that specializes in the care of STS underwent a 30-minute training session using cases not included in the subsequent imaging review. The readers were told that the lesions that they would be assessing would either be STSs (primary, recurrent, or metastatic) or BFs (post-operative collection, hematoma, or abscess). The readers independently reviewed the images on dedicated workstations (Advantage Workstation (AW), GE Healthcare, Milwaukee, WI) and were allowed to review all PET and CT images in the selected study using custom and adjustable window settings, but were blinded to historical data, other studies, and the final diagnoses. The readers were asked to 1) assess the SP of a specific lesion on a 4-point scale (thin, moderate, thick, or solid) independently of the degree of ^18^F-FDG avidity on a score sheet (Fig. [1](#F1){ref-type="fig"}), and 2) make a subjective determination based on their experience as to whether each lesion represented an STS.

Standardized uptake value (SUV) was calculated as

where *A* is the tissue tracer activity in microcuries per gram, *I* is the injected radiotracer dose in millicuries, and *M* is the patient mass in kilograms. The maximum SUV (SUV~max~) for each lesion was measured by placing a 3D volume of interest around each lesion.

Statistical Analysis
--------------------

Kruskal-Wallis tests were used to compare the 4-point ordered avidity scale by reference standard diagnosis, and Wilcoxon rank-sum tests were used to compare SUV~max~. Kappa statistics were used to assess reader agreement of SP. Agreement was classified by convention based on Kappa values as slight (0.00-0.2), fair (0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80), and almost perfect (0.81-1.00) [@B43].

Logistic regression analysis was used to evaluate the diagnostic utility of using SUV~max~ alone and combined with SP for differentiation of STS from BF. The resultant receiver operating characteristic (ROC) curves are provided. The discrimination analysis for SUV~max~ alone used frequentist inference with Delong\'s 95% confidence interval (CI) [@B44] for the area under the ROC curve (AUC). The bootstrapping approach provided in the pROC library was used to compute 95% pointwise CIs for the ROC shape. Youden\'s optimal threshold using SUV~max~ alone is reported [@B45].

Because independent variable SP is assessed with uncertainty among the four readers, a joint model was used to conduct inference using all of the observed information. The combined inference used a Bayesian hierarchical model to integrate over the inherent inter-reader variability for evaluating SP. For each patient, the presence of thick or solid SP was treated as a binary random variable. Let *π~i~* denote the probability that the *i^th^* patient presents thick or solid SP (*i = 1, ..., n*). A conditional multiple logistic regression model was used to adjust the *i^th^* patient\'s log-odds ratio for presence of STS as a linear combination of an intercept, a partial effect modifying SUV~max~, and a partial effect modifying *π~i~*. Beta (1, 1) prior distributions were assumed for the *π~i~s* reflecting maximum entropy. Non-informative normal prior distributions were assumed for the intercept and regression coefficients. Results are reported to reflect discrimination of STS in the presence of the estimated inter-reader variability for evaluating SP in the form of marginal 95% pointwise posterior credible intervals (pCI) for the AUC and ROC shape. Summaries of the resultant partial regression coefficients associated SUV~max~ and SP are provided. All statistical analyses were performed using SAS 9.3, R.2.12.2, and OpenBUGS 3.2.1.

Results
=======

There were 100 patients, ranging from 9 to 89 years of age (median age 54 years), with 42 females and 58 males. There were 100 lesions (Table [2](#T2){ref-type="table"}), of which 56 were STSs and 44 were BFs. Of the 56 STSs, 38 (68%) were primary, 14 (25%) were recurrences, and 4 (7%) were metastases. Of the 44 BFs, 32 (72.8%) were post-operative fluid collections, 9 (20.5%) were hematomas, and 3 (6.8%) were abscesses. Of the 9 hematomas 3 were of unknown etiology, 3 related to catheter placement, 2 were related to surgery, and 1 was related to anticoagulation. The abscesses were associated with immunocompromised status in patients receiving chemotherapy, either related to direct inoculation following minor injury or in the setting of systemic bacteremia.

The diagnostic performance of ^18^F-FDG PET-CT using the subjective assessments of the 4 readers is shown in Table [3](#T3){ref-type="table"}. The mean sensitivity of the readers for detection of STSs was 93% (range: 91% - 98%) and the mean specificity was 77% (range: 59% - 91%).

We next assessed the data available in ^18^F-FDG PET studies, including SUV~max~ and SP. The SUV~max~ for the lesions is shown in Fig. [2](#F2){ref-type="fig"}. The median SUV~max~ for all lesions was 5.5 (range: 1.1-33.7). The STSs had a significantly higher SUV~max~ (median 10.7, range: 2.0-33.7) than BFs (median 2.8, range: 1.1-12.3) (p\<0.0001). The median SUV~max~ of abscesses (11.6, range 4.3 -12.3) was higher than that of the other BFs (2.7, range 1.1-8.4) (p=0.009).

The readers scored the SP of the STSs and BFs on the 4-point avidity scale (Fig. [1](#F1){ref-type="fig"}). Reader agreement was substantial (κ = 0. 61) and varied among the different SPs, being highest for the thin SP (κ = 0.70) and lowest for the thick SP (κ = 0.46, Table [4](#T4){ref-type="table"}). Examples of SPs with 100% reader agreement are shown in Fig. [3](#F3){ref-type="fig"}.

The SP of STSs was more likely to be assessed as thick or solid by all readers (p\<0.0001). Modeling the diagnostic efficacy of a system that classified lesions with a thick or solid SP as an STS yielded an inter-reader averaged sensitivity and specificity of 69% and 98%, respectively.

Bayesian multiple logistic regression analysis attained significance for both SUV~max~ and SP. The presence of thick or solid SP resulted in an estimated 14.1-fold increase in the partial odds of STS with 95% pCI=(3.74, 54.1). Moreover, each unit increase in SUV~max~ was associated with a 1.35-fold increase in the partial odds of STS with 95% pCI=(1.18, 1.60).

The ROC curve based on SUV~max~ alone (Fig. [4](#F4){ref-type="fig"}, red curve) produced an AUC=0.89 (95% CI 0.83 - 0.96). The optimal discrimination between STS and BF was at SUV~max~ = 5.15 (Fig. [4](#F4){ref-type="fig"}, red dot), yielding a sensitivity of 84% and specificity of 89%. Classification using both SUV~max~and SP (Fig. [4](#F4){ref-type="fig"}, blue curve) resulted in an AUC=0.96 (95% pCI = 0.94 - 0.98). Comparing the two interval estimates of AUC revealed that the resultant improvement in the discriminability of STS from BF using both SUV~max~ and SP did not achieve statistical significance at the 0.05 level. The average of the subjective assessments for the four readers (Fig. [4](#F4){ref-type="fig"}, see asterisk) and estimated performance of using SP alone (Fig. [4](#F4){ref-type="fig"}, see open circle) were contained within the 95% interval estimates of both ROC shapes.

Discussion
==========

Our results showed that ^18^F-FDG PET-CT is a sensitive (mean 93%, range: 91% - 98%) modality for the differentiation of STSs from BFs (Table [3](#T3){ref-type="table"}). The mean specificity of 77% (range: 59% - 91%) was lower than the sensitivity. However, given the importance of making a prospective diagnosis of a sarcoma, the high sensitivity affirms the value of ^18^F-FDG PET-CT in the early diagnostic workup of patients suspected of having a primary or recurrent sarcoma, especially given that the studies were interpreted in the absence of historical and clinical data. Our results are in the range of sensitivity (91% - 100%) and specificity (73% - 100%) reported in the literature on differentiating STS from benign soft-tissue lesions [@B5], [@B6], [@B16], [@B35], [@B36], [@B46], although these studies included few or no BFs.

We found statistically significant differences in the SUV~max~ of STSs (10.7, range: 2.0-33.7) and BFs (2.8, range: 1.1-12.3). In addition, SUV~max~ was significantly independently associated with STS in the presence of SP.

We also examined the contribution SP to the differentiation of STSs from BFs. SP has not been as extensively investigated as SUV [@B36]-[@B42], and may provide additional information about the biological behavior of soft-tissue lesions on ^18^F-FDG PET [@B37]. SP can be assessed qualitatively or quantitatively. Qualitative assessments of heterogeneity, degree of peripheral nodularity, and apparent peripheral thickness of lesions have been used in the past to differentiate benign from malignant lung [@B38] and peripheral nerve sheath [@B39] tumors, and to distinguish between high-grade and low-grade STSs [@B36]. Quantitative algorithms for objective characterization of SP have been used to estimate prognosis in patients with STSs [@B37], [@B40], [@B41] and to assess treatment response in patients with head and neck cancers [@B42]. Widespread adoption of these quantitative methods has likely been hampered by practical concerns such as time constraints in busy clinical practices. We chose to focus on a qualitative assessment of SP to provide a more readily applied clinical method using an intuitive 4-point scale (Fig. [1](#F1){ref-type="fig"}) for subjective evaluation of SP (Fig. [3](#F3){ref-type="fig"}).

Agreement among the readers in scoring the SPs had a mean κ = 0.61 (range 0.46-0.70). This mild degree of inter-observer variability is likely subjective. STSs were more likely to be assessed as thick or solid across all readers (p\<0.0001), and we found that SP was significantly independently associated with STS in the presence of SUV~max~.

The shape of the ROC curves may suggest that the incorporation of SP (Fig. [4](#F4){ref-type="fig"}, blue curve) improves discrimination of STS from BF compared to SUV~max~ alone (Fig. [4](#F4){ref-type="fig"}, red curve); however, the difference between the AUCs lacked statistical significance, and the shapes of the 95% intervals overlapped. The average of the subjective assessments for the four readers (Fig. [4](#F4){ref-type="fig"}, see asterisk) and estimated performance of using SP alone (Fig. [4](#F4){ref-type="fig"}, open circle) were contained within the 95% interval estimates of both ROC shapes, suggesting that the sensitivity/specificity tradeoffs derived from the subjective assessments of the 4 readers are similar to the tradeoffs provided by the quantitative methods.

Our study has several limitations. First, it was retrospective and ^18^F-FDG PET-CT is not routinely used for detecting abscesses or hematomas in our clinical practice. This likely introduced a selection bias regarding our patient population, which tended to include large numbers of simple post-operative fluid collections (72.8%) detected on routine surveillance, and relatively few hematomas (20.5%) and abscesses (6.8), which are usually characterized by MRI or ultrasound at our institution. Given that inflammatory lesions such as hematomas and abscesses tend to have higher SUV~max~ and present greater diagnostic challenges, our results will need prospective validation with a more diverse population of lesions.

We found an \"optimal\" SUV~max~ threshold of 5.15 for classification of STS using SUV~max~ alone, arbitrarily assuming equal costs for misclassification of a lesion as an STS and a BF. In clinical practice, the implications of a false negative diagnosis of an STS would likely outweigh those of a false positive diagnosis; however, in the interest of objectivity we adopted the more conventional assumption of equal costs in our analysis, avoiding specification of subjective utility weights. In addition, this SUV~max~ threshold should be used with caution, given the variability that exists in SUV measurements across institutions [@B47].

An apparent limitation of our study concerns the inclusion of lesions with the solid SP. It can be argued that these cases present little or no diagnostic challenge, since they would be expected to represent STSs. Given the degree of inter-observer variability for the solid SP (κ = 0.63, Table [4](#T4){ref-type="table"}), our results indicate that this SP is not necessarily straightforward. This may be secondary to the "blooming" effect that is evident when FDG uptake is indicated on fused images.

Conclusion
==========

^18^F-FDG PET-CT is a sensitive modality for the differentiation of STSs from BFs. Multivariate analysis showed that SUV~max~ and SP are both significantly independently associated with STS. Classification schemes based upon SUV~max~, alone or augmented with SP are expected to help effectively discriminate STS.
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![Score sheet used by readers to assess the spatial pattern of ^18^F-FDG avidity (SP) of lesions on a 4-point scale. The readers were also asked to make a determination based on their experience as to whether each lesion represented an STS.](jcav05p0328g001){#F1}

![SUV~max~ by type of lesion. Bars represent the range, boxes represent the 25th-75th percentile range, black circles represent the mean, and horizontal lines represent the median. The median SUV~max~ of STSs was 10.7 (range: 2.0 -33.7). The median SUV~max~ of all BFs was 2.8 (range: 1.1 -12.3). The median SUV~max~ of post-operative fluid collections (Post-op), hematomas, and abscesses were 2.7 (range: 1.1 -8.4), 3.5 (range: 1.3 -5.1), and 11.6 (range: 4.3 -12.3), respectively. \*, statistically significant difference (p \< 0.05).](jcav05p0328g002){#F2}

###### 

Examples of lesions with 100% observer agreement on assessment of SP. **a**Thin SP **a1** A 77-year-old woman with a seroma (arrow) 17 days following excisional nodal biopsy (SUV~max~ = 1.7). **a2** A 66-year-old woman with a seroma (arrow) 3 months following excisional nodal biopsy (SUV~max~ = 2.0). **a3** A 21-year-old man with a seroma (arrow) 10 days following excisional nodal biopsy and hydrocele repair (SUV~max~ = 3.9). **b** Moderate SP: **b1** A 46-year-old man with undifferentiated sarcoma (SUV~max~ = 19.4). **b2** A 38-year-old man with a fungal abscess (SUV~max~ = 11.6). **b3** A 78-year-old woman with recurrent myxoid pleomorphic undifferentiated sarcoma (SUV~max~ = 5.9). **c** Thick SP: **c1** A 67-year-old man with metastatic undifferentiated sarcoma (SUV~max~ = 6.3). **c2** A 65-year-old man with pleomorphic undifferentiated sarcoma (SUV~max~ = 30.3). **c3** A 45-year-old man with synovial sarcoma (SUV~max~ = 10.9). **d** Solid SP: **d1** A54-year-old woman with rhabdomyosarcoma (SUV~max~ = 15.7). **d2** A 43-year-old man with pleomorphic undifferentiated sarcoma (SUV~max~ = 2.7). **d3** A 48-year-old woman with myxoid liposarcoma (SUV~max~ = 2.9).
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![Receiver Operating Characteristics (ROC) Curves. ROC curves and 95% CIs for SUV~max~ (red) and SUV~max~ + SP (blue) in the classification of a lesion as an STS. The two CIs overlap. The average performance of the readers (\*) is within the 95% CI of the two curves. The estimated performance of using SP alone (open circle) is also within the 95% CI of the two curves.](jcav05p0328g007){#F4}

###### 

Inclusion criteria for lesions.

  -------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  **Reference Standard**                                                     
                                                                             \- STS: Biopsy
                                                                             \- BFs: Biopsy, or appearance immediately after surgery, or no growth on imaging \> 6 months off therapy.
  **Size \> 3.0 cm**                                                         
  **Location in the extremities (including hips, buttocks and shoulders)**   
  **Image Quality**                                                          
                                                                             \- Lesion completely visualized on PET
                                                                             \- Lack of significant misregistration
  **Absence of confounding lesions**                                         
                                                                             \- Adjacent malignancy in cases of BF
                                                                             \- Adjacent fluid collection in case of STS
  -------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------

###### 

Number and type of lesions studied.

  Lesion                 Number (%)                          
  ---------------------- ----------------------------------- -----------
  Total                  100                                 
  Soft-tissue sarcomas   56                                  
                         Malignant fibrohistiocytic tumors   17 (30.4)
                         Undifferentiated sarcomas (NOS)     13 (23.2)
                         Synovial sarcoma                    6 (10.7)
                         Liposarcoma                         5 (8.9)
                         Leiomyosarcoma                      4 (7.2)
                         PNET/Ewing sarcoma                  3 (5.4)
                         Alveolar soft part sarcoma          2 (3.6)
                         Epithelioid sarcoma                 2 (3.6)
                         MPNST                               2 (3.6)
                         Clear cell sarcoma of soft tissue   1 (1.8)
                         Rhabdomyosarcoma                    1 (1.8)
  BFs                    44                                  
                         Post-operative fluid collection     32 (72.8)
                         Hematoma                            9 (20.5)
                         Abscess                             3 (6.8)

Histological subtypes of sarcomas according to the American Joint Committee on Cancer classification [@B48]. MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise specified; PNET, primitive neuroectodermal tumor.

###### 

Reader performance by subjective assessment.

  Reader   Sensitivity   Specificity
  -------- ------------- -------------
  1        91 %          91 %
  2        93 %          75 %
  3        98 %          59 %
  4        91 %          82 %
  Mean     93 %          77 %

###### 

Reader Agreement of Spatial Pattern of ^18^F-FDG Avidity

  Pattern    Kappa   p-value
  ---------- ------- ----------
  Thin       0.70    \<0.0001
  Moderate   0.60    \<0.0001
  Thick      0.46    \<0.0001
  Solid      0.63    \<0.0001
  All        0.61    \<0.0001
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